Alpha Tau Medical Ltd. has announced promising interim results from its REGAIN trial, which evaluates its innovative Alpha DaRT treatment for recurrent glioblastoma. The results, shared during an investor call on November 16, 2026, indicate that all eight patients treated are alive, showcasing a 100% survival rate. This development is significant as it underscores the potential of Alpha DaRT in addressing a challenging form of cancer.
Alpha Tau Medical Ltd., incorporated in Israel, operates under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. The company trades on the Nasdaq under the ticker symbols DRTS and DRTSW. Recent filings indicate that Alpha Tau is categorized as an accelerated filer and an emerging growth company.
The filing reveals that during the investor call, the company discussed the interim results from the REGAIN trial, which were presented at the SNO 2026 Annual Meeting. According to the report, "8 of 8 patients alive; 100% feasibility; 6 of 6 objective responses in assessed patients." This data reflects a significant achievement for Alpha Tau, as it suggests that the Alpha DaRT treatment is not only feasible but also effective in eliciting responses in patients.
This update may impact various stakeholders, including patients suffering from recurrent glioblastoma, healthcare providers, and investors in the medical technology sector. The positive results could enhance patient treatment options and encourage further investment in innovative cancer therapies.
Looking ahead, Alpha Tau Medical has not specified the next steps following this filing. However, the ongoing analysis of the REGAIN trial data will likely continue to shape the company's future strategies and potential regulatory submissions.
Read Next
TOYO Co., Ltd Reports Q3 2026 Results in Latest Filing
NN Inc. to Present at Craig-Hallum Alpha Select Conference
Fresco Gutierrez Diego sells shares of StoneCo Ltd.
Ciena Corp appoints new Chief Product Officer amid changes
Shell plc's Dick Boer Nominated for Philips Supervisory Board
Rumsey Reports Major Stock Transactions at Cummins Inc









